tixagevimab/cilgavimab 作为暴露前预防在血液系统恶性肿瘤患者中预防重症 COVID-19 的有效性:一项捷克回顾性多中心研究 Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech PubMed 2023/12/14 发表Ann HematolQ3 · IF 2.3(JCR 2025) 人群:成人靶点:CD20靶点:CD38技术:CAR-T技术:造血干细胞血液系统恶性肿瘤